• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

POLL: Which 2022 Psoriasis FDA Approval Were You Most Excited About?

Poll

Click here to answer this week's poll.

Which 2022 Psoriasis FDA Approval Were You Most Excited About?

Deucravacitinib
Tapinarof cream
Roflumilast cream
Spesolimab (generalized pustular psoriasis)
Recent Videos
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
Omar Noor, MD, FAAD, is featured in this series.
Omar Noor, MD, FAAD, is featured in this series.
Omar Noor, MD, FAAD, is featured in this series.
Omar Noor, MD, FAAD, is featured in this series.
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
Related Content
UCB Presents 4-Year Data on Bimekizumab for Plaque Psoriasis

UCB Presents 4-Year Data on Bimekizumab for Plaque Psoriasis

Article
The Cutaneous Connection: An Inside Look of the Inclusive Atlas

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

Podcast
Psoriasis within the US Hispanic Population: What Can Be Done to Diversify Clinical Data?

Psoriasis within the US Hispanic Population: What Can Be Done to Diversify Clinical Data?

Article
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

Podcast
‘Next-Generation TYK2 Inhibitor’: Insights into Zasocitinib

‘Next-Generation TYK2 Inhibitor’: Insights into Zasocitinib

Article
FDA Accepts Roflumilast Foam sNDA for Scalp and Body Psoriasis

FDA Accepts Roflumilast Foam sNDA for Scalp and Body Psoriasis

Article
© 2024 MJH Life Sciences

All rights reserved.